Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 6/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25111018 | 0.94 | CYP19A1 (0.45) | GBA1CYP19A1GGPS1HRH4HRH3 | |
| SCHEMBL25109752 | 0.94 | CYP19A1 (0.45) | GBA1CYP19A1GGPS1HRH4HRH3 | |
| SCHEMBL25109359 | 0.87 | ALDH1A1 (0.40) | GBA1CYP19A1L3MBTL1ADRB2HRH4 | |
| SCHEMBL25480884 | 0.86 | CYP19A1 (0.41) | GBA1CYP19A1L3MBTL1HRH4HRH3 | |
| SCHEMBL10081203 | 0.85 | L3MBTL1 (0.51) | GBA1CYP19A1L3MBTL1GGPS1HRH4 | |
| SCHEMBL3560934 | 0.83 | CYP19A1 (0.56) | GBA1CYP19A1L3MBTL1GGPS1HRH4 | |
| SCHEMBL22794477 | 0.83 | HRH4 (0.43) | GBA1CYP19A1ADRB2HRH4HRH3 | |
| SCHEMBL9926333 | 0.82 | CYP19A1 (0.58) | GBA1CYP19A1L3MBTL1GGPS1HRH4 | |
| SCHEMBL19478927 | 0.82 | CYP19A1 (0.58) | GBA1CYP19A1L3MBTL1GGPS1HRH4 | |
| SCHEMBL25110391 | 0.82 | CYP19A1 (0.58) | GBA1CYP19A1L3MBTL1GGPS1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | GBA1 2990/4885CYP19A1 4266/4885L3MBTL1 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.